Dietary Supplement Contract Manufacturer & CDMO — Europe.

Your market vision. Our scientific capital.

  • EBM formulation from scratch — no house blends, no shared databases
  • ISO 9001 · ISO 22000 · ISO 27001 · FDA Registered — audited to 2029
  • 100% IP transfer, permanent — your formula, your brand, no licensing fees
17 years R&D 350+ brands launched 0 quality complaints 40+ countries
17

Years of R&D

350+

Brands Launched

0

QA Complaints

40+

Countries Served

Science you can verify.

Our R&D pedigree is documented in stock exchange filings, Tier-1 media, and international awards — not marketing brochures.

University of Cambridge

Cambridge Lab–to–Scale Partner

We scaled micellar technology created by Lycotec Ltd — a spin-off of Cambridge’s Department of Pathology — from laboratory to industrial production. Documented in Adiuvo Investments S.A. annual reports filed with the Warsaw Stock Exchange (GPW).

International Awards 2025

Rome & NCBiR Recognition

International Leader in Scientific Excellence in Dietary Supplement Manufacturing (Palazzo Brancaccio, Rome). Best in Business Award under the honorary patronage of NCBiR — Poland’s National Centre for Research and Development.

Forbes & Proprietary AI

“Algorithm in a Capsule”

Forbes profiled our proprietary AI toxicology verification system — a safety layer that screens every formula for ingredient interactions and cocktail effects. Not generic ChatGPT. Purpose-built, trained on peer-reviewed medical literature.

CEO publications & media features

Forbes Polityka Biotechnologia.pl Świat Przemysłu Farmaceutycznego

Olimpia Baranowska, MSc — CEO & Lead Formulation Scientist

We don’t just manufacture.
We publish, lecture, and peer-review.

Olimpia Baranowska, MSc — CEO & Lead Formulation Scientist at Olympia Biosciences™

Lead Formulation Scientist & CEO

Olimpia Baranowska, MSc Eng.

Ph.D. Candidate in Medical Sciences · Gdańsk University of Technology

Publishing scientist, international conference speaker, and peer-reviewer. Featured in Forbes for pioneering the AI-verified toxicology system that screens every formula at Olympia Biosciences™. Scaled micellar technology from a University of Cambridge spin-off (Lycotec Ltd) to industrial production — documented in Warsaw Stock Exchange filings.

EBM Formulation AI Toxicology Cambridge Scale-Up Rome 2025 Award

We do not own brands.

We build yours.

Here is what nobody tells you before you sign a contract manufacturing dietary supplements agreement: Most supplement CDMOs sell finished products under their own labels — competing directly with you, using the same formulas, the same supply chain, the same production lines. We refused to play that game. Olympia Biosciences™ will never develop or market a consumer brand. Your formula. Your IP. No exceptions.

AI-Verified Safety Layer

A single overlooked interaction can trigger a recall. After our scientists design each formula from scratch, our proprietary AI screens every combination for cocktail effects and toxicological risks.

Medical-Grade Manufacturing

Your patients trust you. That trust cannot survive a contaminated batch. Every production run is verified by HPLC and GC-MS chromatography. Five ISO certifications — because your reputation demands it.

Full IP Transfer. Period.

Imagine investing months in a custom formula — only to discover your manufacturer owns the rights. Every formula we create is transferred to you permanently. No licensing traps. No "house blends."

Why CDMO Selection Is a High-Stakes Decision

The three ways the wrong CDMO destroys your brand.

Before you sign any contract manufacturing agreement, these are the specific failure modes that have ended supplement brands.

IP Theft

Your formula leaks. Your competitor launches first.

Most supplement CDMOs operate their own consumer brands. They use the same formulation scientists, the same databases, the same supply chains. There is no legal or technical barrier preventing your formula from appearing under a different label within 12 months. This is not theory — it is the documented reality of standard CMO contracts.

Our ISO 27001:2023 certified information security and contractual zero-conflict-of-interest policy make this structurally impossible.

Quality Failure

One bad batch. Your brand never recovers.

A product recall in the supplement industry costs between €200K and €2M in direct expenses. The reputational damage is permanent. Most generic CMOs do not perform batch-specific HPLC/GC-MS release testing — they rely on Certificate of Conformity from raw material suppliers. That is not verification. That is assumption.

Every batch we release is verified by in-house HPLC and GC-MS analysis. Zero QA complaints since 2009 across 350+ brands.

Scale Failure

You launch. Your CDMO cannot keep up.

A successful launch creates demand your manufacturer was never designed to fulfill. Single production lines create single points of failure. A breakdown, a contamination, a regulatory hold — any of these can halt your supply chain permanently and cede your market position to competitors.

Three independent softgel encapsulation lines provide 300% technical redundancy. We have never missed a committed delivery.

Production Infrastructure — Poland, EU

Two specialized manufacturing facilities.

One for dietary supplements and medical food. One for nutricosmetics — cosmetics of clinical significance. Two separate QA chains. One zero-defect culture.

Facility I — Dietary Supplements & FSMP

CDMO Core: Supplements & Medical Food

Our primary GMP-certified manufacturing facility handles the complete supplement production lifecycle — from evidence-based formulation through HPLC/GC-MS quality release. Specializes in dietary supplements and FSMP (Food for Special Medical Purposes) under EU Regulation 2016/128. Three independent softgel lines, clean-room capsule production, and a dedicated analytical QA/QC laboratory.

Dietary Supplements FSMP / Medical Food Softgel, capsules & powders 100M+ units / month
Gdynia, Poland · EU · ISO 9001 · ISO 22000 · FDA Registered

Facility II — Nutricosmetics

Medical Cosmetics & Beauty-From-Within

A dedicated facility for nutricosmetics — oral and topical cosmetics of clinical significance. Separate production environment, separate analytical chain. Handles beauty-from-within formulations, dermocosmetics, and medical-grade skincare backed by clinical data and formulated under the same evidence-based rigor as our pharmaceutical-grade supplements.

Nutricosmetics (Oral) Medical-Grade Cosmetics Dermocosmetics ISO 22716 GMP
Poland · EU · ISO 22716 · Separate QA Chain

Side-by-side: CDMO vs CMO vs Research Lab

Not all contract manufacturers are the same.

Here is exactly how Olympia Biosciences™ differs — in writing, with specifics.

Criteria Research Lab Generic CMO Olympia Biosciences™
Custom formula from scratch Yes, lab-scale only Pre-made blends only ✓✓ Full EBM formulation + scale-up
Industrial-scale manufacturing Outsourced, IP at risk Yes, high volume ✓✓ 5k–500k+ units, HPLC/GC-MS verified
Full IP transfer to client ~ Often retains formula rights ✓✓ 100% permanent, ISO 27001 protected
Zero own consumer brands ~ Most CDMOs compete with clients ✓✓ Contractual zero conflict of interest
FSMP / medical food production ~ Rarely ✓✓ Specialized, lab-grade protocols
AI toxicology verification ✓✓ Proprietary, Forbes-featured system
Quality complaints since 2009 Industry average varies 0

40+ countries · 350+ brands · every industry

Who partners with Olympia Biosciences™

Production at Scale — Gdynia, Poland

Where precision becomes production.

Three independent softgel encapsulation lines. HPLC/GC-MS batch release. Zero deviations since 2009. This is not capacity for the sake of capacity — it is redundancy engineered so that your launch date is never a manufacturing variable.

100M+

capsules per month

3

independent softgel lines

0

QA deviations since 2009

Explore Scale-Up Capabilities

We do not work with everyone.

Seventeen years. Zero complaints. Not one. That is not a marketing line — it is a direct mathematical consequence of the projects we refuse.

We will not put our name behind a generic composition that already sits on ten thousand shelves under ten thousand different labels. We will not manufacture with commodity-grade raw materials just because a procurement department wants to shave twelve cents per unit. We will not compress a stability protocol because a launch date was promised before the science was finished.

There is a reason our clients build brands that command premium pricing in highly competitive markets. There is a reason their products survive regulatory scrutiny in jurisdictions where others fail. There is a reason some of them started with a single SKU and now operate across forty countries.

It is not luck. It is what happens when the formulation, the raw materials, the delivery system, and the manufacturing precision are all engineered to be strictly unreplicable. We say no to more projects than we accept. The clients who pass that threshold tend to stay for years.

Proprietary AI Safety System — Forbes Featured

Every formula screened before a single patient sees it.

Our AI toxicology verification system is not ChatGPT. It is purpose-built and trained exclusively on peer-reviewed pharmacological literature. It screens every formula for ingredient interactions, cocktail effects, and toxicological risks — as a final safety gate after our scientists complete R&D.

"Algorithm in a Capsule" — Forbes

Explore Our Technology

From molecule to market.

01

R&D Discovery

Your clinical insight becomes a stable formula. We test ingredient interactions and verify safety through our proprietary AI.

Your clinical or commercial insight is reverse-engineered into a stable, scalable formula. We audit every active ingredient for sourcing purity, bioavailability data, and known interactions. Our proprietary AI toxicology system performs a final screening pass — an additional safety gate beyond any standard in the industry.

You receive: Proof-of-Concept formula · Ingredient safety dossier · AI interaction report

02

Scale-Up

From 5k to 500k units. Softgels, blisters, clean-label formulations. Every batch perfectly matches the last.

Pilot batch is scaled to full commercial production on the same validated equipment. PPQ (Process Performance Qualification) ensures batch-to-batch consistency from 5,000 to 500,000+ units. You are never surprised at scale.

You receive: Pilot batch · PPQ validation protocol · Scale-up report

03

QA / QC

HPLC/GC-MS batch verification and Full Certificate of Analysis for pharmaceutical-grade quality assurance.

Every production batch is released only after HPLC and GC-MS chromatographic analysis confirms active compound concentrations. Full Certificate of Analysis (CoA) issued per batch, covering identity, potency, purity, and microbiological safety.

You receive: HPLC/GC-MS Certificate of Analysis · Stability data · Release documentation

04

Compliance

We handle GIS notification, EFSA health claims, and export documentation (FSC). You focus on the science.

We handle GIS notification, EFSA health claims compliance, and export documentation (Free Sale Certificate). Your product arrives market-ready in EU, U.S. (FDA), and 40+ international markets. You focus on the brand. We handle the regulatory maze.

You receive: GIS notification · EFSA claim compliance · FSC export documents

Delivery Technologies

Every advanced delivery format. One facility.

We manufacture across the full spectrum of modern supplement delivery — from softgel encapsulation to liposomal nanotechnology.

Softgel Capsules — Gelatin & HPMC plant-based · 3 independent lines
Liposomal Encapsulation — SUVs 50–100 nm · spray-dried pro-liposomes
Nano-Micellization — Cambridge spin-off technology · WSE validated
Enteric HPMC Capsules — Targeted release · acid-resistant coating
FSMP Clinical Formats — EU Reg. 2016/128 · oncology & metabolic
Powder & Effervescent — Blend, granulation, effervescent tablet
View All Delivery Technologies

Since 2009 — Gdynia, Poland

Built in Poland. Trusted in 40+ countries.

From a single formulation lab in Gdynia to a dual-facility CDMO serving premium brands on six continents — the same uncompromising commitment to evidence-based science since day one.

2009

Year founded

2

Production facilities

5

ISO certifications

0

QA complaints

Olympia Biosciences™ — premium softgel capsule manufacturing technology, Poland EU
Currently accepting new R&D partnerships for Q3–Q4 2026

Your vision meets our science.

Two capitals. One product.

You bring market intelligence and clinical insight. We bring seventeen years of R&D depth, proprietary AI safety verification, and manufacturing precision that has never produced a single complaint. Together, we engineer products that command premium pricing and survive regulatory scrutiny in any jurisdiction.

Frequently Asked Questions

What does a dietary supplement contract manufacturer do?
A dietary supplement contract manufacturer is a third-party specialist that handles the complete supplement production lifecycle on behalf of a brand — from initial R&D formulation to the final packaged product. As a full CDMO, Olympia Biosciences™ provides end-to-end supplement contract manufacturing: custom EBM formulation, analytical validation (HPLC/GC-MS), high-volume scale-up, and 100% IP transfer to the client.
What is a Dietary Supplement CDMO in Europe and how does Olympia Biosciences™ differ?
A CDMO (Contract Development and Manufacturing Organization) handles both R&D formulation and full-scale production. Olympia Biosciences™ differs by operating as a strict zero conflict of interest supplement manufacturer — we do not own any consumer supplement brands, ensuring complete IP protection for our B2B partners.
What certifications does Olympia Biosciences™ hold?
We hold ISO 9001:2015 (Quality Management), ISO 22000:2018 (Food Safety), ISO 22716:2009 (GMP for Cosmetics), ISO 27001:2023 (Information Security), integrated HACCP/GMP/GHP per Codex Alimentarius, and U.S. FDA registration. All ISO certificates are audited by POLCARGO GROUP Ltd and valid until 2029.
Can Olympia Biosciences™ manufacture FSMP (Foods for Special Medical Purposes)?
Yes. We specialize in FSMP contract manufacturing under laboratory-grade protocols. Our facility is equipped for complex formulations including softgel encapsulation, liposomal delivery, and nano-micellization — all verified by HPLC and GC-MS analytical methods.
What is the AI-Verified Safety Layer?
Every formula is designed by our R&D scientists. As an additional verification step, our proprietary AI screens each formulation for ingredient interactions, cocktail effects, and toxicological risks. This provides an extra safety layer beyond standard industry practice.
Does Olympia Biosciences™ provide full IP transfer?
Yes. Every formula we develop is built from scratch for your project and transferred to you permanently. No licensing fees, no shared databases, no house blends. Your intellectual property is protected by ISO 27001 information security and iron-clad NDAs from day one.
What is the difference between a CDMO and a CMO in supplement manufacturing?
A CMO (Contract Manufacturing Organization) executes production to your specifications. A CDMO (Contract Development and Manufacturing Organization) handles both R&D formulation and full-scale production. Olympia Biosciences™ operates as a full CDMO — engineering custom EBM formulas from scratch, validating scale-up with PPQ standards, and manufacturing all under one ISO-certified roof with 100% IP transfer to the client.
Which countries does Olympia Biosciences™ serve as a supplement CDMO?
We serve clients in 40+ countries across Europe, the United States, Canada, the Middle East, Asia-Pacific, and Latin America. Our GMP-certified manufacturing facility is located in Gdynia, Poland (EU), and our products ship globally with complete regulatory documentation for EU, U.S. FDA, and international market requirements.
How long does custom supplement formulation take at Olympia Biosciences™?
Custom formulation timelines depend on complexity. A standard EBM supplement formula (capsule or powder blend) takes 4–8 weeks for the R&D phase. Advanced delivery systems such as liposomal or nano-micellar formulations require 8–16 weeks. The first production batch begins after Proof of Concept validation and stability testing are complete.
What supplement delivery forms does Olympia Biosciences™ manufacture?
We manufacture softgel capsules (gelatin and HPMC plant-based), hard capsules, powder blends, effervescent tablets, liquid formulations, and FSMP products in clinical formats. Our three independent softgel encapsulation lines produce 100M+ capsules per month and have maintained zero QA product complaints since 2009.